跳至主要内容
临床试验/NCT03621709
NCT03621709Unknown不适用

Multicenter Ambispective Study of Clinical Outcomes of the CoreValve™Evolut R™ 34mm System: All Comers Post-market Registry

Fundacin Biomedica Galicia Sur1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2017年8月1日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
100
试验地点
1
主要终点
Efficacy: prosthetic regurgitation at early post TAVI

研究概览

简要总结

With the introduction of the CoreValve™ Evolut R™ 34mm (Medtronic™) prosthesis, patients with severe symptomatic aortic stenosis (AS) and large aortic annulus have become eligible for transcatheter aortic valve implantation (TAVI). The aim of this study is to detect the number of TAVI candidates with large aortic annulus, and to evaluate the feasibility, efficacy, and safety of TAVI using the CoreValve™ Evolut R™ 34mm.

详细描述

With the current transcatheter valves available in the market, is possible to cover a wide range of patients with diverse and complex anatomies. Nevertheless, there is a subgroup of patient with large aortic annulus (diameter > 27 mm), in whom the implant of a transcatheter valve is not possible because there is no valve suitable for such as aortic annulus size.

With the introduction of the CoreValveTM EvolutionTM R 34mm, patients with an aorttic annulus dimension up to 29 mm in diameter have become eligible for TAVI. However, there is a lack of information regarding the number of patient with AS and this particular anatomy of the aortic annulus. Italian and Dutch registries have reported a prevalence between 6.5 to 12.3% with large aortic annulus requiring the previous CoreValveTM 31mm. Yet, there is no reported data regarding this population of patients in Spain. Also, the clinical use of this larger prosthesis covers a wider range of aortic rings and may enchance the procedural challenges, such as a little margin for proper valve placement, more likelihood of interference with mitral valve function and damage to the cardiac conduction system during the prosthesis deployment.

So far, no studies regarding clinical experiences with the CoreValveTM EvolutionTM R 34mm have been published. The scarce information currently available with this new device may be distant from those found in its daily clinical use in non-selected patients. The results of this Spanish nationwide registry will help to answer a scientific need of information regarding acute procedural results and mid

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects ≥ 18 years of age.
  • Subject accepted participate and signed informed consent.
  • Subject with severe symptomatic AS patients selected for TAVI by the Heart Team of each participating hospital.
  • Patients anatomically suitable for the implantation of a CoreValve™ Evolut R™ 34mm with the approved indications by any feasible and appropriate vascular routes.
  • Subject must agree to undergo all follow-up visits

排除标准

  • High probability of non-adherence to the follow-up requirements.
  • Explicit refusal of participation in the registry.

结局指标

主要结局

Efficacy: prosthetic regurgitation at early post TAVI

时间窗: 12 months

Percent of subjects with ≤ mild prosthetic regurgitation at early post-implant (mild, Moderate or Severe)

Safety:Incidence of permanent pacemaker implant rate

时间窗: 12 months

Incidence of permanent pacemaker implant rate, dichotomous qualitative variable: yes/no

Safety: Stroke

时间窗: 12 months

Stroke (disabling), dichotomous qualitative variable: yes/no

次要结局

未报告次要终点

研究者

发起方
Fundacin Biomedica Galicia Sur
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

CoreValve™ Evolut R™ 34 mm System Registry... | 临床试验